2.74
전일 마감가:
$2.74
열려 있는:
$2.76
하루 거래량:
17,377
Relative Volume:
0.09
시가총액:
$7.42M
수익:
$202.00K
순이익/손실:
$-28.96M
주가수익비율:
-4.5667
EPS:
-0.6
순현금흐름:
$-21.85M
1주 성능:
+3.59%
1개월 성능:
+11.84%
6개월 성능:
+2,140%
1년 성능:
+914.81%
AIM ImmunoTech Inc Stock (AIM) Company Profile
명칭
AIM ImmunoTech Inc
전화
352 448 7797
주소
2117 SW Highway 484, Ocala, FL
AIM을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
AIM
AIM ImmunoTech Inc
|
2.74 | 7.42M | 202.00K | -28.96M | -21.85M | -0.60 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
Why AIM ImmunoTech Inc. stock remains top rated2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - newser.com
Will AIM ImmunoTech Inc. (HXB) stock benefit from Fed rate cutsJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - newser.com
Will AIM ImmunoTech Inc. stock keep raising dividendsJuly 2025 News Drivers & Safe Entry Trade Signal Reports - newser.com
Can AIM ImmunoTech Inc. (HXB) stock sustain breakout momentumWeekly Risk Report & Free Verified High Yield Trade Plans - newser.com
How AIM ImmunoTech Inc. (HXB) stock compares with top peersTrade Entry Summary & Long-Term Safe Investment Ideas - newser.com
Can AIM ImmunoTech Inc. (HXB) stock hit consensus price targetsProfit Target & Advanced Swing Trade Entry Alerts - newser.com
How AIM ImmunoTech Inc. stock stacks up against competitorsTrade Performance Summary & Verified Swing Trading Watchlists - newser.com
How AIM ImmunoTech Inc. (HXB) stock performs in volatility spikesMarket Risk Analysis & Reliable Price Action Trade Plans - newser.com
AIM ImmunoTech Secures Patent in Japan Through 2039 for - GlobeNewswire
AIM ImmunoTech Secures Japan Patent for Ampligen in Cancer Treat - GuruFocus
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors - The Manila Times
Novel Cancer Therapy Patent Victory: AIM ImmunoTech's Ampligen Combo Shows Promise in Phase 2 Trials - Stock Titan
Analyzing AIM ImmunoTech (NYSE:AIM) and ZIVO Bioscience (NASDAQ:ZIVO) - Defense World
AIM ImmunoTech Announces Publication of Journal Article On - GlobeNewswire
AIM ImmunoTech's Ampligen Shows Promise in Cancer Treatment - GuruFocus
Breakthrough Cancer Treatment: AIM ImmunoTech's Ampligen + Interferon Shows Promise Against 'Cold' Tumors - Stock Titan
Maxim Group Sees 133% Upside in AIM ImmunoTech Inc. (AIM) - Insider Monkey
AIM ImmunoTech Inc (AIM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):